EpiVax links with Novozymes Biopharma to advance autoimmune diseases treatment
Danish drugmaker Novozymes’ (NZYMB: CO) Veltis albumin-based half-life extension platform will help move Tregitope treatment for autoimmune diseases closer to clinical development.
Privately-held US biotech firm EpiVax and Novozymes Biopharma yesterday announced that they have entered a license agreement for the development of novel treatments for autoimmune diseases. The agreement follows two years of successful feasibility studies and it allows EpiVax to use Novozymes' albumin technologies to develop cutting edge immunotherapies.
EpiVax has identified a set of natural peptide sequences, called Tregitopes, derived from Immunoglobulin G (IgG) that are potent activators of natural T regulatory cells (hence Tregitope). The initial application targeted by the Novozymes/EpiVax collaboration will be the development of a recombinant alternative to intravenous IgG (IVIG) treatment, a global market that exceeded $6 billion in 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze